Memorias del Instituto de Investigaciones en Ciencias de la Salud
versión On-line ISSN 1812-9528
LEGUIZAMON, MA et al. Immune response to an oral vaccine (CVD 103 HGR - BERNA -SWITZERLAND) against cholerain paraguayan volunteers. Mem. Inst. Investig. Cienc. Salud [online]. 2003, vol.2, n.1, pp.39-48. ISSN 1812-9528.
ABSTRACT Cholera remains as an important public health problem in underdeveloped countries. In 1998, more than 1,000,000 cases were notified in Latin America. Paraguay has reported four cases until now. The epidemic has focused the attention to the development of a safe, effective and long lasting cholera vaccine. A live oral attenuated CVD 103-HgR (Inaba serotype, Classical biotype) has been licensed in several countries, including Paraguay. To evaluate the safety and immunogenicity of CVD 103-HgR in Paraguayan volunteers, an study was performed. Forty healthy adults, were recruited in Asuncion, Paraguay to receive a single oral dose (2-6 x 109 cfu) of CVD103-HgR). Serum samples were obtained before, 15 and 30 days alter vaccination. The level of IgG, IgA and IgM antibodies was measured in serum of the volunteers as well as the level of vibriocidal and anti-LPS antibodie. The vaccine was well tolerated and no diarrhea illness was observed in the study. Twenty seven (67.5%) of the 40 volunteers developed serum vibriocidal antibodies. None had vibriocidal titers at baseline, eight (20%) had a reciprocal titer of 320 and only five (12.5%) reached titers equal or higher than 5,120. In the measurement of anti-LPS antibodies, there were not significative results. This is the first study of evaluation of an oral vaccine against cholerae. These results show that the Paraguayan volunteers developed a vibriocidal antibody response. This vaccine could be effective against cholera in our country.
Palabras clave : Vibrio cholerae; oral vaccine; vibriocidal antibodies; Paraguayan volunteers.